Switch theme
Sign up to access all valuation multiples
Shield Therapeutics PLC is a commercial stage specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals that address areas of high unmet medical need. The company's operating segments are based on key products including PT20 and Feraccru, involves development and commercialisation of the Group’s main Feraccru product, and PT20 is used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from the Feraccru segment.
2015
77
LTM Revenue $30.9M
LTM EBITDA -$12.5M
$54.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Shield Therapeutics has a last 12-month revenue (LTM) of $30.9M and a last 12-month EBITDA of -$12.5M.
In the most recent fiscal year, Shield Therapeutics achieved revenue of $43.2M and an EBITDA of -$28.5M.
Shield Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Shield Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $30.9M | XXX | $43.2M | XXX | XXX | XXX |
| Gross Profit | $14.2M | XXX | $20.1M | XXX | XXX | XXX |
| Gross Margin | 46% | XXX | 46% | XXX | XXX | XXX |
| EBITDA | -$12.5M | XXX | -$28.5M | XXX | XXX | XXX |
| EBITDA Margin | -41% | XXX | -66% | XXX | XXX | XXX |
| EBIT | -$13.5M | XXX | -$30.7M | XXX | XXX | XXX |
| EBIT Margin | -44% | XXX | -71% | XXX | XXX | XXX |
| Net Profit | -$16.6M | XXX | -$36.5M | XXX | XXX | XXX |
| Net Margin | -54% | XXX | -84% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $26.4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Shield Therapeutics's stock price is GBP 0 (or $0).
Shield Therapeutics has current market cap of GBP 25.5M (or $34.3M), and EV of GBP 40.3M (or $54.1M).
See Shield Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $54.1M | $34.3M | XXX | XXX | XXX | XXX | $-0.03 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Shield Therapeutics has market cap of $34.3M and EV of $54.1M.
Shield Therapeutics's trades at 1.3x EV/Revenue multiple, and -1.9x EV/EBITDA.
Equity research analysts estimate Shield Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Shield Therapeutics has a P/E ratio of -1.5x.
See valuation multiples for Shield Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $34.3M | XXX | $34.3M | XXX | XXX | XXX |
| EV (current) | $54.1M | XXX | $54.1M | XXX | XXX | XXX |
| EV/Revenue | 1.3x | XXX | 1.3x | XXX | XXX | XXX |
| EV/EBITDA | -3.2x | XXX | -1.9x | XXX | XXX | XXX |
| EV/EBIT | -3.0x | XXX | -1.8x | XXX | XXX | XXX |
| EV/Gross Profit | 2.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.5x | XXX | -0.9x | XXX | XXX | XXX |
| EV/FCF | -8.5x | XXX | -4.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialShield Therapeutics's last 12 month revenue growth is 57%
Shield Therapeutics's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.7M for the same period.
Shield Therapeutics's rule of 40 is -174% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Shield Therapeutics's rule of X is 103% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Shield Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 57% | XXX | 37% | XXX | XXX | XXX |
| EBITDA Margin | -41% | XXX | -66% | XXX | XXX | XXX |
| EBITDA Growth | -72% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -174% | XXX | -9% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 103% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 74% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 117% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Shield Therapeutics acquired XXX companies to date.
Last acquisition by Shield Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Shield Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Shield Therapeutics founded? | Shield Therapeutics was founded in 2015. |
| Where is Shield Therapeutics headquartered? | Shield Therapeutics is headquartered in United Kingdom of Great Britain and Northern Ireland. |
| How many employees does Shield Therapeutics have? | As of today, Shield Therapeutics has 77 employees. |
| Who is the CEO of Shield Therapeutics? | Shield Therapeutics's CEO is Mr. Karl Anders Lundstrom. |
| Is Shield Therapeutics publicy listed? | Yes, Shield Therapeutics is a public company listed on LON. |
| What is the stock symbol of Shield Therapeutics? | Shield Therapeutics trades under STX ticker. |
| When did Shield Therapeutics go public? | Shield Therapeutics went public in 2016. |
| Who are competitors of Shield Therapeutics? | Similar companies to Shield Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Shield Therapeutics? | Shield Therapeutics's current market cap is $34.3M |
| What is the current revenue of Shield Therapeutics? | Shield Therapeutics's last 12 months revenue is $30.9M. |
| What is the current revenue growth of Shield Therapeutics? | Shield Therapeutics revenue growth (NTM/LTM) is 57%. |
| What is the current EV/Revenue multiple of Shield Therapeutics? | Current revenue multiple of Shield Therapeutics is 1.3x. |
| Is Shield Therapeutics profitable? | Yes, Shield Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Shield Therapeutics? | Shield Therapeutics's last 12 months EBITDA is -$12.5M. |
| What is Shield Therapeutics's EBITDA margin? | Shield Therapeutics's last 12 months EBITDA margin is -41%. |
| What is the current EV/EBITDA multiple of Shield Therapeutics? | Current EBITDA multiple of Shield Therapeutics is -3.2x. |
| What is the current FCF of Shield Therapeutics? | Shield Therapeutics's last 12 months FCF is -$4.7M. |
| What is Shield Therapeutics's FCF margin? | Shield Therapeutics's last 12 months FCF margin is -15%. |
| What is the current EV/FCF multiple of Shield Therapeutics? | Current FCF multiple of Shield Therapeutics is -8.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
